Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration

Long-Term P2Y 12 Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention

(2023) Davide Capodanno et al.   CIRCULATION

Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI

(2023) Davide Capodanno et al.   JACC-Cardiovascular Interventions

Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease

(2023) Nishank Jain et al.   VASCULAR PHARMACOLOGY

Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome

(2023) Harsha Teja Perla et al.   American Journal of Cardiovascular Drugs

Negative Impact of ST-Segment Elevation Myocardial Infarction and Morphine Dose on Ticagrelor Uptake and Pharmacodynamics: A Population PK/PD Analysis of Pooled Individual Participant Data

(2023) Celine Konecki et al.   CLINICAL PHARMACOKINETICS

Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes

(2023) William A.E. Parker et al.   VASCULAR PHARMACOLOGY

Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack

(2023) Jia Zhang et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events

(2023) Felice Gragnano et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome

(2022) Ying Ma et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial

(2022) Davide Capodanno et al.   Journal of the American Heart Association

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

(2022) Amber L. Beitelshees et al.   Journal of the American Heart Association

Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy

(2022) Yaling Han et al.   Circulation-Cardiovascular Interventions

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

(2022) Georg Gelbenegger et al.   Thrombosis Journal

Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial

(2022) Juan F. Iglesias et al.   Cardiology Journal

A Comprehensive Review of the Pleiotropic Effects of Ticagrelor

(2022) Jeffrey Triska et al.   CARDIOVASCULAR DRUGS AND THERAPY

P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

(2022) Giuseppe Andò et al.   JACC-Cardiovascular Interventions

Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study

(2022) Francesco Franchi et al.   JACC-Cardiovascular Interventions

Clinical pharmacology of antiplatelet drugs

(2022) Georg Gelbenegger et al.   Expert Review of Clinical Pharmacology

Assessment of Good Practice Guidelines for Administration of Drugs via Feeding Tubes by a Clinical Pharmacist in the Intensive Care Unit

(2022) Pauline Cavagna et al.   Critical Care Nurse

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease

(2022) Chor-Cheung Tam et al.   Journal of Clinical Medicine

Management of Antithrombotic Therapy after Acute Coronary Syndromes

(2021) Fatima Rodriguez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Antiplatelet Therapy After Acute Coronary Syndrome

(2021) Hassan Kamran et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Extending the Product Label for Ticagrelor: Looking Under the FDA Hood

(2021) Paul W. Armstrong   CIRCULATION

Selatogrel

(2021) Craig J. Beavers et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Orodispersible Ticagrelor in Acute Coronary Syndromes

(2021) Guido Parodi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events

(2021) Alexandra Bálint et al.   STROKE

Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

(2021) Devin L. Brown et al.   STROKE

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives

(2021) Leonardo De Luca et al.   Journal of the American Heart Association

Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers

(2021) Katarzyna Buszko et al.   Frontiers in Physiology

The Effects of Bariatric Surgery and Gastrectomy on the Absorption of Drugs, Vitamins, and Mineral Elements

(2021) Miłosz Miedziaszczyk et al.   Pharmaceutics

Ticagrelor causes false negative functional tests for heparin-induced thrombocytopenia

(2020) Julia JM Eekels et al.   BLOOD

The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

(2020) Masafumi Ono et al.   Clinical Research in Cardiology

Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)

(2020) Diana A Gorog et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial

(2020) Piotr Niezgoda et al.   Cardiology Journal

Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development

(2020) Rocco P. Milluzzo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Selatogrel for Acute Myocardial Infarction

(2020) Johanne Silvain et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

(2020) Marieke Gimbel et al.   LANCET

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome

(2020) Byeong-Keuk Kim et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial

(2020) A H Tavenier et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Platelet Inhibition with Cangrelor and Crushed Ticagrelor in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study

(2019) Francesco Franchi et al.   CIRCULATION

The MOVEMENT Trial

(2019) Manne Holm et al.   Journal of the American Heart Association

Efficacy and Safety of Alternative Oral Administrations of P2Y12‐receptor Inhibitors: Systematic Review and Meta‐analysis

(2019) Matteo Serenelli et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Loading with Oral P2Y12 Receptor Inhibitors: To Crush or Not to Crush?

(2019) Dimitrios Alexopoulos et al.   THROMBOSIS AND HAEMOSTASIS

Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial

(2019) Salahaddin Ubaid et al.   THROMBOSIS AND HAEMOSTASIS

Effects of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the PK and PD Profiles of Ticagrelor in Patients With Coronary Artery Disease Treated With Morphine

(2019) Francesco Franchi et al.   JACC-Cardiovascular Interventions

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

(2019) Joo-Yong Hahn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Chewed or Crushed Administration of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndromes: a Systematic Review and Meta-analysis of Randomized Controlled Trials

(2019) Hourmazd Haghbayan et al.   CARDIOVASCULAR DRUGS AND THERAPY

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

(2019) Stefanie Schüpke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

(2019) P. Gabriel Steg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial

(2019) Moazez J. Marian et al.   Journal of the American Heart Association

The promise of effective P2Y12 platelet receptor pretreatment: Not crushed yet

(2018) Arka Chatterjee et al.   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS

Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea

(2018) Luis Ortega-Paz et al.   CIRCULATION

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine

(2018) Frédéric Lapostolle et al.   American Journal of Cardiovascular Drugs

METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—The METAMORPHOSIS Trial

(2018) Piotr Niezgoda et al.   THROMBOSIS AND HAEMOSTASIS

2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

(2018) Yong Huo et al.   Science Bulletin

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

(2017) Marco Valgimigli et al.   EUROPEAN HEART JOURNAL

Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial

(2017) Christian Schoergenhofer et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia

(2017) Gustavo Jiménez-Brítez et al.   RESUSCITATION

Oral trans-mucosal administration of ticagrelor: is this really the future?

(2017) Fabiana Rollini et al.   THROMBOSIS AND HAEMOSTASIS

Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina

(2017) Malwina Barańska et al.   THROMBOSIS AND HAEMOSTASIS

Prasugrel in critically ill patients

(2017) Christian Schoergenhofer et al.   THROMBOSIS AND HAEMOSTASIS

Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study

(2017) Moshe Katz et al.   THROMBOSIS AND HAEMOSTASIS

Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets

(2017) Dimitrios Venetsanos et al.   THROMBOSIS RESEARCH

The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study

(2017) Hanna Ratcovich et al.   EuroIntervention

Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction

(2017) Elad Asher et al.   JAMA Cardiology

Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia

(2016) Klemen Steblovnik et al.   CIRCULATION

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention

(2016) Fabiana Rollini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial

(2016) Robert F. Storey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y 12 inhibitors really more effective than clopidogrel?

(2016) Guillaume Gouffran et al.   RESUSCITATION

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update

(2015) Renli Teng   CLINICAL PHARMACOKINETICS

Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study

(2015) Dimitrios Alexopoulos et al.   CLINICAL PHARMACOKINETICS

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial

(2015) Jacek Kubica et al.   EUROPEAN HEART JOURNAL

Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers

(2015) Eva-Luise Hobl et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Ticagrelor-related gout: An underestimated side effect

(2015) Nixiao Zhang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers

(2015) Renli Teng et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Double-Blind, Randomized, Prospective Comparison of Loading Doses of 600 mg Clopidogrel Versus 60 mg Prasugrel in Patients With Acute ST-Segment Elevation Myocardial Infarction Scheduled for Primary Percutaneous Intervention

(2015) Uwe Zeymer et al.   JACC-Cardiovascular Interventions

Ticagrelor Crushed Tablets Administration in STEMI Patients

(2015) Guido Parodi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction

(2015) Frantisek Bednar et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Adenosine-Mediated Effects of Ticagrelor

(2014) Marco Cattaneo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

(2014) Gilles Montalescot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety

(2014) Paul P. Dobesh et al.   PHARMACOTHERAPY

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

(2013) Philippe Gabriel Steg et al.   LANCET

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

(2013) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor

(2012) Renli Teng   CLINICAL PHARMACOKINETICS

Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?

(2011) Terry K. W. Ma et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

(2011) Robert F. Storey et al.   EUROPEAN HEART JOURNAL

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers

(2010) Kathleen Butler et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects

(2010) Renli Teng et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes

(2010) Robert F. Storey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor: The First Reversibly Binding Oral P2Y12Receptor Antagonist

(2009) Steen Husted et al.   Cardiovascular Therapeutics

Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease

(2009) Paul A. Gurbel et al.   CIRCULATION

P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use

(2009) L. Wallentin   EUROPEAN HEART JOURNAL

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

(2009) Alan D. Michelson et al.   EUROPEAN HEART JOURNAL

Crushed Clopidogrel Administered via Nasogastric Tube Has Faster and Greater Absorption than Oral Whole Tablets

(2009) M. UROOJ ZAFAR et al.   JOURNAL OF INTERVENTIONAL CARDIOLOGY

Intravenous Platelet Blockade with Cangrelor during PCI

(2009) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction

(2008) Antonius A.C.M. Heestermans et al.   THROMBOSIS RESEARCH